Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (627)	12/8/2005 2:00:46 PM
From: tuck	Read Replies (1) \| Respond to of 933

Kosan is getting whacked on these interim results for EPO D, which do look kind of middling: >>SAN ANTONIO, Dec. 8 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN - News) today announced interim results of an ongoing Phase II clinical trial indicating that KOS-862 administered as a monotherapy has demonstrated anti-tumor activity in patients with anthracycline and taxane pretreated metastatic breast cancer. KOS-862 is a polyketide that inhibits cancer cells by the same mechanism as paclitaxel. Interim results were presented today at the 28th Annual San Antonio Breast Cancer Symposium. The poster presentation #1087 "A Phase II Study of KOS-862 (Epothilone D) in Anthracycline and Taxane Pretreated Metastatic Breast Cancer: Updated Results" included preliminary efficacy results from 41 evaluable patients in the Phase II clinical trial, all of whom had advanced metastatic disease and had previously failed treatment with anthracycline and taxane. Twelve percent of the evaluable patients (five patients) treated with KOS-862 had confirmed partial responses (PR), including two patients with hepatic (liver) metastases who exhibited a greater than 50 percent tumor reduction according to RECIST (Response Evaluation Criteria In Solid Tumors). The median duration of response for the five PR patients was 10.1 weeks. An additional three patients (7.3% of the evaluable patients) had stable disease greater than four cycles. Three of five confirmed PR patients had adjuvant taxane therapy; four of five had received prior taxane therapy for metastatic disease. "The interim Phase II results of KOS-862 as a monotherapy treatment for metastatic breast cancer reveal encouraging anti-tumor activity in patients previously treated with anthracyclines and taxanes," said Daniel V. Santi, M.D., Ph.D., Kosan Chairman and Chief Executive Officer. "We continue to accrue patients in this study and look forward to the presentation of full data upon trial completion." In the Phase II clinical trial, KOS-862 was administered by 90 minute intravenous infusion weekly for three weeks every four weeks at a dose of 100 mg/m2. No grade 4 adverse events were observed. Neurotoxicities were the most common safety events related to KOS-862 therapy with peripheral neuropathy the most common neurotoxicity; the Grade 3 incidence was less than 12%. A Phase Ib/II combination study of weekly KOS-862 and weekly Herceptin® in patients with HER-2 overexpressing metastatic breast cancer is ongoing. About KOS-862 KOS-862 (Epothilone D) is a polyketide that inhibits cancer cell growth in vitro by a mechanism similar to paclitaxel, and preclinical models have shown the compound to be effective against paclitaxel-resistant tumors. In addition to the Phase II monotherapy trial in breast cancer, KOS-862 continues to be evaluated in a Phase I/II combination trial with Herceptin®. Roche and Kosan initiated a global development and commercialization agreement for KOS-862 and other compounds in the epothilone class in September 2002. According to the agreement, Roche has the worldwide exclusive right to market and sell KOS-862, KOS-1584, a second epothilone drug candidate currently in Phase I clinical trials, and other epothilone analogs owned by or licensed to Kosan for the treatment of cancer; Kosan will co-develop and has the right to co-promote Kosan/Roche epothilone products in the U.S. for the treatment of cancer.<< snip The good thing is the claim of activity versus taxane resistant tumors seems to be warranted. Cheers, Tuck